Luis delaCruz-Merino

25PUBLICATIONS
121CO-AUTHORS
NanomedicineTumour immunologyHaematological tumoursInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag

|Mar 06, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

|Feb 13, 2025
Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial.

Sara Fernández-Castillejo, Joan Badia, Luís de la Cruz-Merino

|Sep 27, 2024
Role of Nutrients Regulating Myeloid Derived Suppressor Cells in Cancer: A Scoping Review.

Beatriz Pérez-Peláez, Carlos Jiménez-Cortegana, Luis de la Cruz-Merino

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

|Mar 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

Dirk Schadendorf, Jason John Luke, Paolo A Ascierto

Pageof 5

Frequent Collaborators

10 joint publications

Victor Sánchez-Margalet

6 joint publications

Paolo A Ascierto

5 joint publications

Carlos Jiménez-Cortegana

5 joint publications

Jean-Jacques Grob